X0202 SCHEDULE 13G 0001105806 XXXXXXXX LIVE Common Stock 10/13/2026 0002002988 Retension Pharmaceuticals, Inc. 76135H100 1104 West Broad Street, #1029 Falls Church VA 22046 Rule 13d-1(c) Laurence W. Lytton X1 617207 0 617207 0 617207 7.4 IN Percentage calculated based on 8,331,599 shares of Common Stock outstanding following the closing of the Issuer's initial public offering on October 13, 2026, as reported in the Prospectus filed by the Issuer on October 9, 2026. Retension Pharmaceuticals, Inc. 1104 West Broad Street, #1029, Falls Church, VA 22046 Laurence W. Lytton 467 Central Park West New York, NY 10025 United States Y 617,207 7.4 617,207 0 617,207 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Laurence W. Lytton /s/ Laurence W. Lytton 10/15/2026